@Biocartis_
Rudi Pauwels Chief Executive Officer, Director

Rudi Pauwels, PhD (M), is the chairman and Chief Executive Officer of the Biocartis and founded the company in 2007. Mr. Pauwels is a serial entrepreneur who also co-founded several other European biotech companies, including Tibotec, Virco and Galapagos Genomics. Starting his career as a researcher at the internationally renowned Rega Institute for Medical Research in Leuven, Mr. Pauwels has focused for more than two decades on the search and development of anti-HIV drugs and the development of diagnostic tools that enable personalized HIV treatment. He is (co)-author of more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Mr. Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium. Pursuant to the Shareholders’ Agreement, Mr. Pauwels was appointed to the board upon the proposal by Coöperatieve AESCAP Venture I U.A., RMM S.A., Advent Private Equity Fund IV, Benaruca and BIOSPV Limited.

Hilde Windels Deputy CEO, Managing Director

Hilde Windels, Msc. (F) is Deputy CEO and Managing Director of Biocartis. She has close to 20 years of experience in biotech with a track record of building and structuring organisations, private fundraising, M&A, public capital markets and business and corporate strategy. From 2011 until Sept 2015, she was Biocartis’ CFO. From 2009 to mid-2011, she worked as independent CFO for several private biotech companies. From 1999 to 2008, Mrs. Windels was CFO of publicly-listed Devgen. She also served on the boards of Devgen, MDxHealth and FlandersBio and currently is a member of board of Erytech and VIB. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.

Rudi Mariën Chairman, Non-Executive Director

Rudi Mariën is a non-executive director of Biocartis. He is also President and Managing Director of Gengest BVBA and Biovest Comm.VA. He was the Vice President of Cerba European Lab. Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different listed and private biotech companies. Mr. Mariën was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories including the Barc Group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceutical studies. Mr. Mariën holds a degree in pharmaceutical sciences from the University of Ghent, Belgium and a degree in clinical biology from the University of Ghent, Belgium. Pursuant to the Shareholders’ Agreement, Mr. Mariën was appointed to the board upon the proposal by Coöperatieve AESCAP Venture I U.A., RMM S.A., Advent Private Equity Fund IV, Benaruca and BIOSPV Limited. 

Roald Borré Non-Executive Director

Roald Borré is a non-executive director of Biocartis. Mr. Borré started his professional career at the Financieel Economische Tijds newspaper as a financial analyst specialized in high-tech companies, particularly in the ICT and biotech fields. He was responsible for the launch of Wall Street Invest, a weekly with a focus on Nasdaq-listed (mainly) biotech and ICT companies. In 1999, he joined Puilaecto Private Bankers as Senior Fund Manager, where he was in charge of the Biotechnology Fund and managed various investments in the therapeutics and diagnostics field, a position he held until 2006. In 2011, after five years as an entrepreneur, Mr. Borré joined the ParticipatieMaatschappij Vlaanderen as Business and Fund Manager of the TINA fund that focuses on industrial projects with a high degree of innovation and the potential to transform, now adding co-Head of Venture Capital and permanent representative of PMV NV, statutory manager of PMV-TINA Comm.VA to his responsibilities. He is on the board of different TINA portfolio companies and a member of several advisory boards. Mr. Borré holds a Master in Financial and Commercial Sciences (specialisation Accountancy) from EHSAL Management School, Belgium. Pursuant to the Shareholders’ Agreement, Mr. Borré was appointed to the board upon the proposal by ParticipatieMaatschappij Vlaanderen and PMV-TINA Comm.VA.

Peter Piot Independent Director

Peter Piot is an independent director of Biocartis. He is also Director at the London School of Hygiene & Tropical Medicine. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008, and was an Associate Director of the Global Programme on AIDS of the WHO. Under his leadership, UNAIDS became the chief advocate for worldwide action against AIDS, also spear heading UN reform by bringing together 10 UN systems organizations. In 1976 he co-discovered the Ebola virus in Zaïre. Mr. Piot also led research on HIV/AIDS, sexually transmitted diseases and women’s health and has held positions as professor of microbiology and of public health at various institutions. Mr. Piot has received numerous scientific and civil awards and has published over 550 scientific articles and 16 books. He holds amongst others an M.D. from the University of Ghent, Belgium, a Ph.D. in Microbiology from the University of Antwerp, Belgium and a Diploma of Tropical Medicine from the Antwerp Institute of Tropical Medicine, Belgium.

Renaat Berckmoes Independent Director

Renaat Berckmoes is an independent director of Biocartis. He is also a non-executive director at Primacom AG and FPIM-SFPI and a partner at Fortino CVA. Mr. Berckmoes also has held finance positions at Telenet, being CFO from 2006 to 2013. Mr. Berckmoes holds a Master in Business Economics and a Master in Maritime Economics from the University of Antwerp, Belgium and a Master in Political & Social Sciences from the Katholieke Universiteit Leuven, Belgium.

Mark Shaffar Independent Director

Mark Shaffar is an independent director of Biocartis. He has 38 years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories from 1977 to 2014, including Divisional Vice-President of Acquisitions and Licensing. Mr. Shaffar holds an MM in Management Policy, Finance from Northwestern University—Kellogg Graduate School of Management, the United States and a BS in Biochemistry the University of Wisconsin-Madison, the United States.

Hilde Eylenbosch Chief Commercial Officer, Director

Hilde Eylenbosch is a Senior Business Executive with over 25 years of experience in marketing, product innovation, cross functional businesses and organisational leadership in the life sciences industry. Over the last 5 years, she held the roles of Chief Commercial Officer at Alere Inc and was President of Alere International reporting to the COO. Hilde Eylenbosch holds a degree as Medical Doctor (University of Ghent, Belgium) and  successfully completed the General Management Program at Harvard Business School.

Rudi Pauwels Chief Executive Officer, Director

Rudi Pauwels, PhD (M), is the chairman and Chief Executive Officer of the Biocartis and founded the company in 2007. Mr. Pauwels is a serial entrepreneur who also co-founded several other European biotech companies, including Tibotec, Virco and Galapagos Genomics. Starting his career as a researcher at the internationally renowned Rega Institute for Medical Research in Leuven, Mr. Pauwels has focused for more than two decades on the search and development of anti-HIV drugs and the development of diagnostic tools that enable personalized HIV treatment. He is (co)-author of more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Mr. Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium. Pursuant to the Shareholders’ Agreement, Mr. Pauwels was appointed to the board upon the proposal by Coöperatieve AESCAP Venture I U.A., RMM S.A., Advent Private Equity Fund IV, Benaruca and BIOSPV Limited.

Hilde Windels Deputy CEO, Managing Director

Hilde Windels, Msc. (F) is Deputy CEO and Managing Director of Biocartis. She has close to 20 years of experience in biotech with a track record of building and structuring organisations, private fundraising, M&A, public capital markets and business and corporate strategy. From 2011 until Sept 2015, she was Biocartis’ CFO. From 2009 to mid-2011, she worked as independent CFO for several private biotech companies. From 1999 to 2008, Mrs. Windels was CFO of publicly-listed Devgen. She also served on the boards of Devgen, MDxHealth and FlandersBio and currently is a member of board of Erytech and VIB. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.

Ewoud Welten Chief Financial Officer

Ewoud Welten, Msc. (M), joined Biocartis as Chief Financial Officer in September 2015. Coming from international investment bank Kempen & Co where he worked as Vice President Corporate Finance, he has a proven track record in the Life Sciences and Healthcare sector as a corporate financier, in which position he managed numerous international capital market transactions including IPOs, secondary fundraisings and M&A transactions.

 

Ewoud holds a Master Degree in Financial Economics (distinction) from the Erasmus University Rotterdam, the Netherlands. 

Ulrik Cordes EVP Pharma Collaborations & Companion Diagnostics

Ulrik Cordes,MSc (M), is EVP Pharma Collaborations and Companion Diagnostics of Biocartis. Mr. Cordes has special experience in strategy, commercial partnering, global go-to market strategies and M&A activities. Prior to joining Biocartis, he held the position of Global Sales & Marketing Director Slides & Specialty Glass at Thermo Fisher Scientific. He has also held a number of positions at Dako, including that of Vice President Marketing Operations and Vice President Asia Pacific & Export Region. At Dako, Mr. Cordes speer-headed M&A transactions including the Dako-Cytomation merger and the Cytologix acquisition. He also successfully led Dako’s market expansion through commercial partnering and the establishment of subsidiaries in amongst others China and Brazil. Mr. Cordes holds a Master of Science in Biochemistry from the University of Copenhagen, Denmark and a Bachelor of Commerce from Copenhagen Business School, Denmark.

Erwin Sablon R&D and Alliance Management

Erwin Sablon, PhD, MBA (M), joined Biocartis as Director of Diagnostics Development and Alliance Management in June 2010. In August 2012, he took on the role of Head of Applied Research and Development. He is now responsible for all Biocartis internal and external life sciences R&D activities, and for managing the relationships with the company’s development partners.

 

Prior to joining Biocartis, Erwin held the position of Director Project Management at Ablynx N.V. (Gent, Belgium) from 2008-2010. He also gained extensive experience in in vitro diagnostics (IVD) development of molecular diagnostic assays during his 18 years at Innogenetics NV (Gent, Belgium), where he held various R&D management positions, including at the departments of infectious diseases, virology and microbiology. Erwin holds a PhD in Molecular Biology from the University of Ghent and an Executive MBA from the Vlerick Leuven-Gent Management School.

Reginald Van Genechten Manufacturing & Supply Chain

Reginald Van Genechten joined Biocartis as Head of Manufacturing and Supply Chain in March 2016. Prior to joining Biocartis, Reginald held positions as, amongst others, Head of Technical Operational Excellence at McNeil (US based, part of JnJ) and Senior Director Johnson&Johnson Global Supply Chain.

 

He has over 25 years of cross-cultural healthcare experience in Operational Excellence, with an outstanding track record of improving processes to excellence, extensive compliance knowledge (including Consent Decree), achieving superior business results and building competency and sustainable capabilities.

 

Reginald holds a Master Degree in Engineering from University of Brussels and is a certified Master Black Belt in Lean and Black Belt in Six Sigma.

Susy Spruyt Human Resources

Susy Spruyt, Msc. (F), joined Biocartis as Human Resources Director in 2015. Prior to joining Biocartis, Susy held progressive HR roles primarily in the biotech and pharmaceutical industry. Susy holds a Master Degree in Law from VUB University of Brussels.

Erik Vossenaar Business Development

Erik Vossenaar, PhD, joined Biocartis in 2010. As VP Business Development, his responsibilities include partnering and licensing. He played a key role in establishing the company’s partnership model since the very beginning.

  

Erik has a proven track record in the development of molecular diagnostic platforms. Before joining Biocartis, he worked at Philips where he headed the molecular diagnostic assay development team, and afterwards became responsible for Business Development and Technology Strategy for Philips’ Molecular Diagnostics Business Unit. Erik had a pivotal role in the development of Philips Molecular Diagnostics platform, which was acquired by Biocartis in 2010.

 

Erik obtained his Master’s degree in Chemistry from the Radboud University Nijmegen (1999). In 2004 he obtained his PhD at the department of Autoimmune Biochemistry at the same university.

Hilde Eylenbosch Chief Commercial Officer, Director

Hilde Eylenbosch is a Senior Business Executive with over 25 years of experience in marketing, product innovation, cross functional businesses and organisational leadership in the life sciences industry. Over the last 5 years, she held the roles of Chief Commercial Officer at Alere Inc and was President of Alere International reporting to the COO. Hilde Eylenbosch holds a degree as Medical Doctor (University of Ghent, Belgium) and  successfully completed the General Management Program at Harvard Business School.

Geert Maertens Chairman SAB

Geert Maertens joined Biocartis in 2009 as Chief Scientific Officer. He plays an important role in assay pipeline development and external research collaborations in major fields such as cancer and infectious, neurological, genetic and metabolic diseases.

Geert started his career at Innogenetics in 1990, where he initiated the hepatitis-C program. He was head of the company’s Infectious Diseases Business Unit, which developed and marketed >20 diagnostic assays for HIV, HBV, HCV and bacterial typing and resistance during his tenure. Geert was put in charge of HBV, HCV, and HPV vaccine and mAb development in 2002. With the incorporation of GENimmune as a therapeutic vaccines specialty subsidiary of Innogenetics in September 2007, he became Vice President Corporate Development, a post he held until 2008.

 

Geert holds a Master's in Biology from the University of Gent (1984). He continued his studies with Prof. Walter Fiers, working on engineered recombinant hemagglutinin vaccines for universal protection against influenza, and obtained his PhD in 1989. Geert frequently lectures at international meetings, and is an inventor with more than 20 HCV and HBV patent families. He is a reviewer for several scientific journals, evaluates project applications for several European agencies, and has (co-)authored over 85 peer reviewed papers.

Eric Van Cutsem Scientific Advisor

Eric Van Cutsem is currently Professor of Internal Medicine at the University of Leuven (Belgium). He is also head of the Digestive Oncology Department at the University Hospital (Gasthuisberg, Leuven) and a Board member of the Leuven Cancer Institute and the Department of Oncology (KU Leuven).

 

Eric trained in internal medicine and gastroenterology as well as specialized in GI oncology at KU Leuven. He has a large clinical practice in Leuven and leads or is involved in many national and international clinical and translational research projects on gastrointestinal cancer. He holds an MD and a PhD from KU Leuven.

 

He has published more than 340 peer-reviewed articles (on pubmed; H-factor: 70; >20000 citations – January 2013) in prestigious journals such as the New England Journal of Medicine, the Journal of Clinical Oncology and The Lancet. He is co-editor of the reference textbook on gastrointestinal cancer Principles and Practice of Gastrointestinal Oncology (Second edition, 2008), and is/has been an editorial board member of numerous leading journals, including the Journal of Clinical Oncology, Annals of Oncology, and European Journal of Cancer. He is Associate Editor of Targeted Oncology and Editor of European Journal Cancer since January 2011.

 

Eric is a member of several scientific organizations. He is/was a member of the Scientific Program Committee and/or Educational Committee of ASCO, ASCO-GI Cancers Symposium, ESMO and ECCO. He is also a member of the ESMO faculty and joined the ESMO Executive Board on July 1, 2011. He served as Secretary of the European Organisation for Research and Treatment of Cancer – Gastrointestinal Cancer (EORTC-GI) Group from 2000-2003, and as Chair from 2003-2007. He is Chairman of PETACC (Pan-European Trials on Adjuvant Colon Cancer) since 2008, Board member of EORTC since 2009, President of the European Society of Digestive Oncology (ESDO) and Co-chair of the European Neuro-Endocrine Tumour Society (ENETS) Registry. He also chairs the colon cancer prevention task force of the Flemish government (B) and is President of BGDO (Belgian Group Digestive Oncology) and FAPA (Familial Adenomatous Polyposis Association). Eric Van Cutsem is the founder and Chair of the Scientific Committee of the World Congress on Gastrointestinal Cancer in Barcelona (in partnership with ESMO) since 2005.

Josep Tabernero Scientific Advisor

Josep Tabernero heads the Medical Oncology Department of the Vall d’Hebron University Hospital in Barcelona and is Director of the Vall d’Hebron Institute of Oncology.

 

Josep holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is very actively involved in translational research and pharmacodynamic Phase I studies with molecular targeted therapies. He is especially devoted to Phase I and II pharmacodynamic endpoint studies with novel agents that target membrane receptors, including the EGFR family and IGF-1R, the PI3K and ERK signaling pathways, as well as downstream cytoplasmic and intra-nucleus effectors such as Mdm2/p53 and aurora kinase.

 

On the hypothesis that each tumor has an independent genetic identity, his research group very actively participates in the development of molecular therapies that target specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR, IGF1-R, etc.) for patients displaying genetic lesions or pathway dysregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments as well as markers of primary resistance (de novo) and secondary treatment. At the preclinical level, his research group is developing new xenograft models with explant tumors from patients ('xenopatients') in mice in order to mimic the patient’s disease and study tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

 

Joseph is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He also is a member of different Editorial Boards, including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology. He has (co)authored approximately 250 peer-reviewed papers. He is/has been on the Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO and WCGIC meetings.

Alberto Bardelli Scientific Advisor

Alberto Bardelli is Professor of Oncological Sciences at the University of Torino School of Medicine and Director of the Laboratory of Molecular Genetics at the Institute for Cancer Research and Treatment (Turin, Italy).

 

Alberto and his laboratory at the Institute for Cancer Research and Treatment (IRCC) in Turin (IT) have pioneered the generation of human X-MAN™ cell lines harboring subtle kinase mutations that make it possible to accurately predict responses to appropriately targeted agents in patients.

 

Recently, Prof. Bardelli and colleagues discovered that KRAS mutations impart secondary resistance to anti-EGFR therapies in colon cancer and that the mutations can be detected non-invasively in the blood of patients months before progression of the cancer can be measured by radiographic approaches. A future focus of his lab is to find appropriately tailored drug combinations to overcome acquired resistance to targeted therapies.

 

A future focus of his lab is to define other resistance mechanisms in patients and find appropriately tailored drug combinations that target them.

Patrick Pauwels Scientific Advisor

Patrick Pauwels is Professor of Pathology at Antwerp University Hospital. He is Director of the Molecular Pathology Unit. He is also a consultant on soft tissue pathology in the Netherlands (IKZ), and a member of the AACR and several other scientific organizations. He is an advisor to the Belgian Ministry of Health (lung cancer diagnosis and treatment working group).

 

Patrick holds a medical degree (1985) from the University of Leuven (Belgium), where he also received his training in surgical pathology following a two-year residency in internal medicine. After working many years at the Stichting PAMM, Eindhoven (NL), he joined the Pathology Department of Maastricht University Hospital (NL). He also holds a PhD in Medical Sciences from the University of Leiden (NL).

 

After four years on the staff of Ghent University Hospital (Belgium), he moved to Antwerp. He is Co-director of CORE (Center for Oncology Research, Antwerp University). Professor Pauwels has done extensive research in the field of pathology, particularly in the molecular pathology of cancer, and is the author and co-author of some 100 peer-reviewed papers on this topic. His lab, as a central pathology reference lab, is involved in several trials. Recently, it screened some 4,000 lung cancers for ALK gene rearrangement using FISH tests.

Pasi Jänne Scientific Advisor

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He currently works in the Lowe Center for Thoracic Oncology at DFCI. 

 

His main research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents.

Michael Press Scientific Advisor

Dr. Michael F. Press is a board certified pathologist who has authored or co-authored more than 180 papers and is recognized for his work in characterizing molecular genetic alterations of breast cancer. He is the co-leader of the Women’s Cancers Program at the USC/Norris Comprehensive Cancer Center. He is a Surgical Pathologist at the USC+Los Angeles County Hospital and the USC Norris Comprehensive Cancer Center where he is a Professor of Pathology and holds the Harold E. Lee Chair in Cancer Research. He was formerly an Assistant Professor and Associate Professor of Pathology and a Surgical Pathologist at the University of Chicago (1981-1987), where he received both his M.D., and Ph.D. degrees.

 

Dr. Press is the director of a reference laboratory (USC Breast Cancer Analysis Laboratory) engaged in private practice pathology on a referral basis (1988-present). In this laboratory he evaluates prognostic markers and predictive markers as well as histopathology used in making treatment decisions for women with breast cancer. He is the director of the central laboratory for the Cancer International Research Group (CIRG), a clinical trials organization that evaluates new therapies in predominantly breast cancer patients but also conducts trials in several other cancers including gastric cancer.

 

His particular area of research interest is in molecular alterations of breast and gynaecologic cancers, especially those that have the potential to be important in either diagnostic or therapeutic decision-making for patient management. The most prominent area of activity for his 
laboratory has been in the study of the human epidermal growth factor receptor type 2 (HER-2) in breast and other cancers. He 
published his first paper in this area in 1989 (Science 244: 707-712, 1989) and his laboratory is still actively contributing to this area as well as to the conduct of clinical trials evaluating HER-2 as a target for therapy.He is active in teaching medical students, graduate students, postdoctoral fellows and resident physicians.As the Co-Leader of the Women's Cancers Program at the USC Norris Cancer Center, he is responsible for coordinating research activities of basic scientists, clinical scientists, prevention scientists and epidemiologists and for presenting progress in competing renewal grant proposals for our NCI-funded 
Comprehensive Cancer Center.

Jean-Louis Vincent Scientific Advisor

Dr Vincent is Professor of intensive care at University of Brussels, and intensivist in the Department of Intensive Care at the Erasme University Hospital in Brussels. Specialist in Internal Medicine, he spent two years of training at the University of Southern California with Prof. Max Harry Weil.

 

Dr Vincent is Professor of intensive care at University of Brussels, and intensivist in the Department of Intensive Care at the Erasme University Hospital in Brussels. Specialist in Internal Medicine, he spent two years of training at the University of Southern California with Prof. Max Harry Weil.

 

Dr. Vincent has signed more than 800 original articles, some 300 book chapters and review articles, and 850 original abstracts, and has edited 86 books. He is co-editor of the Textbook of Critical Care (Elsevier Saunders, 7th Edition) and the “Encyclopedia of Intensive Care Medicine” (Springer).

 

Dr. Vincent is the editor-in-chief of "Critical Care", "Current Opinion in Critical Care", and "ICU Management". He is member of the Editorial Boards of about 30 journals including "Critical Care Medicine" (senior editor), American Journal of Respiratory and Critical Care Medicine (AJRCCM), "PLoS Medicine", "Lancet Infectious Diseases", "Intensive Care Medicine", "Shock", and "Journal of Critical Care".

 

Dr. Vincent is President of the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM). He is a Past-President of the Belgian Society of Intensive Care Medicine (SIZ), the European Society of Intensive Care Medicine (ESICM), the European Shock Society (ESS), and the International Sepsis Forum (ISF). He is member of the Royal Medical Academy of Belgium.

 

For 34 years he has organized an International Symposium on Intensive Care and Emergency Medicine which is held every March in Brussels.

 

He has received the Distinguished Investigator Award of the Society of Critical Care Medicine, the College Medalist Award of the American College of Chest Physicians, was the Recipient of the "Society Medal”(lifetime award) of the European Society of Intensive Care Medicine and has received the prestigious Belgian scientific award of the FRS-FNRS (Prix Scientifique Joseph Maisin-Sciences biomédicales cliniques).

Bert Niesters Scientific Advisor

Bert Niesters (1958) studied biology and chemistry in Nijmegen, the Netherlands. After obtaining his PhD in Utrecht (Prof.dr. M. Horzinek and Prof.dr. B. van der Zeijst, 1987) on the molecular epidemiology of infectious bronchitis virus, he worked as a post-doctoral fellow with Prof. dr. Jim Strauss at the California Institute of Technology (Pasadena, USA) on the replication of Alphaviruses. He received a Niels Stensen fellowship (The Netherlands) and an E.S. Gosney fellowship (CalTech) during this period.

 

After returning to the Netherlands (1989), he became a research associate in medical microbiology at the Diagnostic Medical Center (Delft), but moved back to clinical virology as a senior research associate in 1991 at the University Medical Center Rotterdam (Head Prof.dr. Ab Osterhaus). From 1993 till 2007, he was responsible for the molecular diagnostics unit. During this period, he has been involved in the discovery and characterization of several new viruses and variants. In 2007, he became professor and director of the new laboratory of Clinical Virology within the Department of Medical Microbiology at the University Medical Centre Groningen.

 

He has been actively involved in the implementation and development of new technologies like real-time amplification and automation within clinical virology. He has been focusing of molecular diagnostics and its use in a transplant setting as well in monitoring treatment of hepatitis viruses.

 

He is active as a board member in several national and international societies . Since 2000, he is scientific advisor and executive member within QCMD (Quality Control of Molecular Diagnostics). He is also an auditor for the Council of Accreditation. Furthermore, he is an executive member of the Dutch Society of Medical Microbiology and Editor-in-Chief of the Journal of Clinical Virology.